Sue D. Pedersen

11.3k citations

49 papers · 4.2k indexed · 7 hit papers · h-index 21

Endocrinology, Diabetes and Metabolism top 0.2%
- Diabetes Treatment and Management 28
- Diabetes Management and Research 6
Pharmacology top 0.5%
- Pharmacology and Obesity Treatment 24
Physiology top 2%
- Diet and metabolism studies 14
Endocrine and Autonomic Systems top 5%
- Regulation of Appetite and Obesity 3
Pharmacy top 2%
- Obesity and Health Practices 4
Molecular Biology
- Metabolism, Diabetes, and Cancer 18
Surgery
- Bariatric Surgery and Outcomes 5

Co-authors: Ildiko Lingvay Ofri Mosenzon Ole Kleist Jeppesen Andreas L. Birkenfeld Melanie J. Davies Sean Wharton Mette S. Thomsen Cees J. Tack
Cited by: Endocrinology, Diabetes and Metabolism Pharmacology Physiology
Partner nations: Canada Denmark United States

In The Last Decade

Sue D. Pedersen

47 papers receiving 4.1k citations

Hit Papers

7 papers align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2025 Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
2024 Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial
2023 Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
2021 Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
2021 Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
2019 Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
2018 Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial

Peers

Countries citing papers authored by Sue D. Pedersen

Since Specialization

Citations

This map shows the geographic impact of Sue D. Pedersen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sue D. Pedersen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sue D. Pedersen more than expected).

Fields of papers citing papers by Sue D. Pedersen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sue D. Pedersen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sue D. Pedersen. The network helps show where Sue D. Pedersen may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Sue D. Pedersen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Sue D. Pedersen Line = papers co-authored together Sue D. Pedersen links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™‐1 and ‐2) Sean Wharton,Carel W. le Roux,Mikhail Kosiborod,Elke Platz,Martina Brueckmann,Ania M. Jastreboff,Samina Ajaz Hussain,Sue D. Pedersen,Luiza Borowska,Anna Unseld,Isabel M. Kloer,Lee M. Kaplan	2024	11
2	Association entre une meilleure perte de poids et une meilleure amélioration de la fonction physique Patrick Ritz,A. Sharma,Jakob B. Bjorner,Robert F. Kushner,Tolga ORAL,Sue D. Pedersen,Domenica Rubino,L. von Huth Smith,Sean Wharton,Niels Zeuthen	2023	1
3	Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists Ronald Goldenberg,Jeremy Gilbert,Priya Manjoo,Sue D. Pedersen,Vincent Woo,Julie A. Lovshin	2023	16
4	How to apply the Canadian Obesity Clinical Practice Guidelines to people with type 2 diabetes Sue D. Pedersen	2023	0
5	Relationship between body weight change and glycaemic control with tirzepatide treatment in people with type 2 diabetes: A post hoc assessment of the SURPASS clinical trial programme Sue D. Pedersen,Francesco Giorgino,Guillermo E. Umpierrez,Vivian T. Thieu,Ángel Rodríguez,Claudia Nicolay,Laura Fernández Landó,Chrisanthi A. Karanikas,Jacek Kiljański	2023	11
6	TOLERABILITY AND WEIGHT REDUCTION OF TIRZEPATIDE IN ADULTS WITH OBESITY OR OVERWEIGHT Domenica Rubino,Sue D. Pedersen,Lisa Connery,Adam Stefański,Dachuang Cao,Jochen Brumm,Russell Griffin,Raleigh Malik,Christophe Longuet	2023	1
7	Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trialbreakdown → Juan P. Frías,Srikanth Deenadayalan,Lars Erichsen,Filip K. Knop,Ildiko Lingvay,Stanislava Macura,Chantal Mathieu,Sue D. Pedersen,Melanie J. Davies	2023	193
8	Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial Vanita R. Aroda,Jens Aberle,Lars Bardtrum,Erik Christiansen,Filip K. Knop,Sanaz Gabery,Sue D. Pedersen,John B. Buse	2023	67
9	Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trialbreakdown → David C.W. Lau,Lars Erichsen,Ann Marie Ocampo Francisco,Altynai Satylganova,Carel W. le Roux,Barbara McGowan,Sue D. Pedersen,Kirsi H. Pietiläinen,Domenica Rubino,Rachel L. Batterham	2021	162
10	A Cross-sectional Survey to Assess Reasons for Therapeutic Inertia in People With Type 2 Diabetes Mellitus and Preferred Strategies to Overcome It From the Perspectives of Persons With Diabetes and General/Family Practitioners: Results From the MOTION Study Paulina K. Wrzal,Amir A. Mohseni,Carl Fournier,Ronald Goldenberg,Debbie Hollahan,Susie Jin,Sue D. Pedersen,Michael Vallis,Andrean Bunko,Varun Myageri,Atif Kukaswadia,Calum S. Neish,Noah Ivers	2021	4
11	Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trialbreakdown → Melanie J. Davies,Louise Færch,Ole Kleist Jeppesen,Arash Pakseresht,Sue D. Pedersen,Leigh Perreault,Julio Rosenstock,Iichiro Shimomura,Adie Viljoen,Thomas A. Wadden,Ildiko Lingvay	2021	806
12	Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial W. Timothy Garvey,Andreas L. Birkenfeld,Dror Dicker,Geltrude Mingrone,Sue D. Pedersen,Altynai Satylganova,Dorthe Skovgaard,Danny Sugimoto,Camilla Jensen,Ofri Mosenzon	2020	139
13	Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trialbreakdown → Patrick M. O’Neil,Andreas L. Birkenfeld,Barbara McGowan,Ofri Mosenzon,Sue D. Pedersen,Sean Wharton,Charlotte Giwercman Carson,Cecilie H. Jepsen,Maria Kabisch,John Wilding	2018	574
14	Efficacy of a liquid low-energy formula diet in achieving preoperative target weight loss before bariatric surgery Lone Nielsen,Mette S. Nielsen,Julie Berg Schmidt,Sue D. Pedersen,Anders Sjödin	2016	24
15	Effects of RYGB on energy expenditure, appetite and glycaemic control: a randomized controlled clinical trial Julie Berg Schmidt,Sue D. Pedersen,Nikolaj Ture Gregersen,Lasse S Vestergaard,Mette S. Nielsen,Christian Ritz,Sten Madsbad,Dorte Worm,Dorte Lindqvist Hansen,Trine Ryberg Clausen,Jens F. Rehfeld,Arne Astrup,Jens J. Holst,Anders Sjödin	2015	64
16	Metabolic complications of obesity Sue D. Pedersen	2013	58
17	Reduction of misclassification rates of obesity by body mass index using dual‐energy X‐ray absorptiometry scans to improve subsequent prediction of per cent fat mass in a Caucasian population Sue D. Pedersen,Arne Astrup,Ib M. Skovgaard	2011	3
18	Comparison of 150-mm versus 100-mm visual analogue scales in free living adult subjects Jean‐Philippe Chaput,Jo‐Anne Gilbert,Nikolaj Ture Gregersen,Sue D. Pedersen,Anders Sjödin	2010	26
19	Portion Control Plate for Weight Loss in Obese Patients With Type 2 Diabetes Mellitus Sue D. Pedersen	2007	74
20	Stress levels experienced by the parents of enterally fed children Sue D. Pedersen,Hannah Parsons,Deborah Dewey	2004	60

About Sue D. Pedersen

Sue D. Pedersen is a scholar working on Endocrinology, Diabetes and Metabolism, Pharmacology and Pharmacy, having authored 49 papers that have together received 4.2k indexed citations. Recurring topics across this work include Diabetes Treatment and Management (28 papers), Pharmacology and Obesity Treatment (24 papers), Metabolism, Diabetes, and Cancer (18 papers), Diet and metabolism studies (14 papers), Diabetes Management and Research (6 papers), Bariatric Surgery and Outcomes (5 papers), Obesity and Health Practices (4 papers) and Regulation of Appetite and Obesity (3 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (3.0k citations), Pharmacology (1.5k citations) and Physiology (1.0k citations). Sue D. Pedersen has collaborated with scholars based in Canada, Denmark and United States. Frequent co-authors include Ildiko Lingvay, Ofri Mosenzon, Ole Kleist Jeppesen, Andreas L. Birkenfeld, Melanie J. Davies, Sean Wharton, Mette S. Thomsen, Cees J. Tack, Freddy G. Eliaschewitz and Mansoor Husain.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact